Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divestment is part of BASF’s strategic portfolio optimization
Exploring new opportunities within the fast-growing market of microfluidics
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
The company has received the GMP Certification after successful closure of the inspection
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
This facility marks a significant milestone in transforming the global food industr
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Subscribe To Our Newsletter & Stay Updated